ACRS Key Statistics, Chart & Performance
The current stock price of ACRS is 2.65 USD. In the past month the price decreased by -11.96%. In the past year, price increased by 7.29%.
ACRS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.39 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.73 | 493.40B | ||
| MRK | MERCK & CO. INC. | 12.36 | 270.22B | ||
| PFE | PFIZER INC | 7.95 | 144.59B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.3 | 110.79B | ||
| ZTS | ZOETIS INC | 20.4 | 57.00B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.89 | 23.46B | ||
| VTRS | VIATRIS INC | 5.32 | 14.28B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.79 | 11.83B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.59B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.36B |
Related stock screener links
About ACRS
Company Profile
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 64 full-time employees. The company went IPO on 2015-10-07. The firm is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. The company has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).
Company Info
ACLARIS THERAPEUTICS INC
701 Lee Road, Suite 103
Wayne PENNSYLVANIA 19087 US
CEO: Neal Walker
Employees: 64
Phone: 14843247933
ACLARIS THERAPEUTICS INC / ACRS FAQ
What does ACRS do?
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 64 full-time employees. The company went IPO on 2015-10-07. The firm is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. The company has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).
What is the stock price of ACLARIS THERAPEUTICS INC today?
The current stock price of ACRS is 2.65 USD.
What is the dividend status of ACLARIS THERAPEUTICS INC?
ACRS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACRS stock?
ACRS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for ACRS stock?
The Revenue of ACLARIS THERAPEUTICS INC (ACRS) is expected to decline by -27.07% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of ACRS stock?
ACLARIS THERAPEUTICS INC (ACRS) has a market capitalization of 287.13M USD. This makes ACRS a Micro Cap stock.
Can you provide the upcoming earnings date for ACLARIS THERAPEUTICS INC?
ACLARIS THERAPEUTICS INC (ACRS) will report earnings on 2026-02-25, after the market close.
ACRS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ACRS. When comparing the yearly performance of all stocks, ACRS is one of the better performing stocks in the market, outperforming 84.85% of all stocks.
ACRS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACRS. ACRS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ACRS Financial Highlights
Over the last trailing twelve months ACRS reported a non-GAAP Earnings per Share(EPS) of -1.38. The EPS decreased by -165.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -80.71% | ||
| ROE | -117.97% | ||
| Debt/Equity | 0 |
ACRS Forecast & Estimates
13 analysts have analysed ACRS and the average price target is 7.82 USD. This implies a price increase of 195.1% is expected in the next year compared to the current price of 2.65.
For the next year, analysts expect an EPS growth of 64.01% and a revenue growth -27.07% for ACRS